Identify at least one – possibly two – progressable lead series meeting DNDi lead stage criteria for visceral leishmaniasis.
last phase of drug development
updated 29 Feb 2020
In February 2016, Daiichi Sankyo and DNDi launched a High-Throughput Screening project of 40,000 compounds from Daiichi Sankyo with the goal of discovering anti-leishmaniasis and anti-Chagas disease compounds, identifying three compound series.
Get our latest news, personal stories, research articles, and job opportunities.